Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch

This page shows the latest Deal Watch news and features for those working in and with pharma, biotech and healthcare.

The M&A trend in pharma

The M&A trend in pharma

The lion's share of deal-making in 2014 continued to revolve around Western markets. ... Read more about pharma's M&A activity in the latest Deal Watch article.

Latest news

  • The hunted now hunt: biotechs become buyers The hunted now hunt: biotechs become buyers

    Biotech deals feature in our latest Deal Watch article.

  • Biologics buoyant

    This continues the biologics trend noted in previous Deal Watch reviews. ... One deal of note during this period was the entry of Bayer Healthcare's dermatology business, Intendis, into the aesthetic dermatology area.

  • Orphan drug focus

    During this period, GSK closed its deal with Nabi for NicVax, a nicotine addiction vaccine in phase III (this was announced in the Deal Watch article on page 15 of the ... P2. 960. Cellzome/GSK. inflammatory disease. Platform. 690. Ariad/Merck.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Novartis has a deal with Spark to market Luxturna in Europe, and is therefore at the forefront of not only the groundbreaking R&D behind cell and gene therapy, but is

  • Deal Watch October 2018

    When writing this bimonthly edition of Medius’s Deal Watch I have been struck by how often the words 'it’s unusual.' have appeared. ... Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for.

  • Deal Watch January 2018

    and a third undisclosed discovery stage programme.  More details on the financials for the deal are summarised below. ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal Watch over the last few months but focused more on

  • Pharma deals continue to slide Pharma deals continue to slide

    Deal Watch investigates. There is plenty of evidence that the number and value of biopharma M&A and licensing deals in 2016 and 2017 is declining. ... This month Deal Watch reviews the potential impact of some of the macroeconomic factors and the impact

  • Deal Watch - May 2017 Deal Watch - May 2017

    due diligence had identified the issues Abbott had chosen to sign the deal. ... In both cases the upfront is around 44% of the total deal value.

More from intelligence
Approximately 78 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics